X4 Pharmaceuticals (XFOR) FCF Margin (2018 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly FCF Margin came in at 236.2% in Q2 2026, up 127931.0% on a YoY basis from N/an in Q2 2025, and up 67.37% quarter-over-quarter from 723.78% in Q1 2026.
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) FCF Margin (2018 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has reported FCF Margin for 5 consecutive years, with 236.2% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin rose 127931.0% year-over-year to 236.2%; the trailing twelve-month figure through Jun 2026 stood at 531.64% (down 19816.0% YoY), and the FY2025 full-year result was 245.26%, up 501094.0% from the prior year.
- FCF Margin climbed to 236.2% in Q2 2026 per XFOR's latest filing, from 723.78% in the prior quarter.
- Across five years, FCF Margin topped out at 42.93% in Q1 2025 and bottomed at 11961.1% in Q2 2024.
- Historically, FCF Margin has averaged 2784.24% across 3 years, with a median of 1515.51% in 2025.
- The sharpest annual moves came in 2025 and 2026: FCF Margin soared 1044559 bps in 2025, then plunged 68085 bps in 2026.
- Over 3 years, FCF Margin stood at 2300.91% in 2024, then jumped by 73 bps to 623.75% in 2025, then surged by 62 bps to 236.2% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 236.2%, 723.78%, and 623.75% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 28.82% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 18.33% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 26.96% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 43.05% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 2.01% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 25.52% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 25.68% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 29.58% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | -236.20% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -236.20% |
| Mar 31, 2026 | -723.78% |
| Dec 31, 2025 | -623.75% |
| Sep 30, 2025 | -1,576.83% |
| Jun 30, 2025 | -1,515.51% |
| Mar 31, 2025 | -42.93% |
| Dec 31, 2024 | -2,300.91% |
| Sep 30, 2024 | -6,077.14% |
| Jun 30, 2024 | -11,961.10% |
| Mar 31, 2020 | -536.07% |
| Dec 31, 2018 | -192.40% |